Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility

Published on :

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that the Maryland Board of Public Works has finalized a $3 million loan facility with Clene Nanomedicine. The loan was provided by the state’s Neighborhood BusinessWorks program within the Maryland Department of Housing and Community Development.

Delfi Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center

Published on :

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center’s Biomarker Development Program, led by Howard I. Scher, MD, FASCO. The agreement creates a framework for Delfi and MSK researchers to work together on a range of projects studying Delfi’s liquid biopsy platform, advancing their shared mission of developing high performing cancer testing.

Spirovant Launches State-of-the-Art Laboratory and Headquarters

Published on :

Spirovant Sciences, a gene therapy company developing treatments for respiratory diseases, including cystic fibrosis (CF), announced today the launch of its new state-of-the-art research laboratory and corporate headquarters in Philadelphia. The new research facilities will allow the company to accelerate development of its lead program targeting CF, support the vector manufacturing process, and build capabilities to grow its platform and pipeline into therapeutic opportunities.

Companies To Watch: Castle Creek Biosciences

Published on :

Castle Creek Biosciences is in late-stage development of gene therapies for rare connective tissue conditions. Its most advanced products, ex vivo therapies based on the company’s proprietary autologous fibroblast technology platform, are localized treatments administered at disease sites. New early-stage products from a recent acquisition have added in vivo, or inside the body, gene therapies, which act against the root causes of targeted diseases. The lead product, D-Fi (coded FCX-007), is now entering late-stage trials for localized treatment of skin blisters and wounds due to dystrophic epidermolysis bullosa (DEB), a rare but horrific inherited condition. Next in line is FCX-013, now in Phase 1/2, treating localized scleroderma. Other ex vivo therapies, including some to treat rare collagen disorders, are in discovery stages tightly focused on rare connective tissue conditions. In vivo gene therapies are in preclinical studies for rare metabolic and liver diseases.

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions

Published on :

SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures. The new funding brings SwanBio’s total financing raised to date to $133 million.

Prominent Emergency Medicine Expert Diku Mandavia, MD Joins BrainScope as Chief Medical Officer

Published on :

Brain injury-assessment device innovator BrainScope announced that Diku Mandavia, MD, has joined the company as Chief Medical Officer. With 28 years of emergency medicine experience and 15 years of commercial medical device experience, Dr. Mandavia is an expert in the importance of point-of-care triage in emergency medicine.

BrainScope Named “Best New Diagnostic Technology Solution” in 2022 MedTech Breakthrough Awards Program

Published on :

Brain-assessment device innovator BrainScope, today announced that it has been selected as “Best New Diagnostic Technology Solution” in the sixth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology markets.

Maryland Stem Cell Research Commission Announces Over $7 Million in Awards to Accelerate Cures

Published on :

The Maryland Stem Cell Research Commission announced it will grant $7,067,409 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland. Awardees submitted proposals to the Commission in response to its Request for Applications (RFAs) for its second round of funding cycle in 2022.

Bucks County’s Pennsylvania Biotechnology Center (PABC) generated $7.3 billion in economic activity over the past six years

Published on :

The nonprofit Pennsylvania Biotechnology Center (PABC), one of the nation’s most successful life sciences incubators, generated $7.3 billion in economic activity in the region during 2016 to 2021, according to a new study commissioned by the PABC’s management.